Trials / Terminated
TerminatedNCT00915278
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
A Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 Administered Intravenously To Adult Patients With Advanced Or Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive to standard therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-04605412 | PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2009-06-08
- Last updated
- 2014-04-04
- Results posted
- 2014-04-04
Locations
7 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00915278. Inclusion in this directory is not an endorsement.